An industry perspective on biomarker-based drug discovery

Size: px
Start display at page:

Download "An industry perspective on biomarker-based drug discovery"

Transcription

1 An industry perspective on biomarker-based drug discovery Advancing Therapeutic Development for Pain and Opioid Use Disorders through Public-Private Partnerships: A Workshop National Academies of Sciences, Washington DC October 12, 2017 Andrew H. Ahn, MD PhD

2 Disclosures The speaker is a full-time employee of Eli Lilly and Company The views expressed in this discussion are those of the speaker and do not represent the views of Eli Lilly and Company Galcanezumab (LY ) is a CGRP neutralizing antibody currently under clinical development by Eli Lilly and Company for the treatment of migraine and cluster headache

3 Overview A story of biomarker-based development CGRP (calcitonin gene-related peptide) and migraine CGRP antagonists and clinical activity Target engagement and clinical efficacy Key enablers of biomarker-based discovery Biomarker assay development Biomarker association with disease state Biomarkers confirming target engagement

4 Biomarker Association with Disease Plasma CGRP associates with migraine attacks and human migraine model Plasma concentration (pmol/l) CGRP Control Migraine no Aura Migraine with Aura Substance P Neuropeptide Y Neuropeptide Goadsby et al, Ann Neurol 1990;28:183 with permission CGRP (pm) Hansen et al, Cephalalgia 2010;30:1179 with permission Edvinsson, CNS Drugs 2001;15:745 with permission

5 Bioassay Development and Validation CGRP Assays using Meso Scale Discovery and Quanterix Platforms MSD Quanterix Signal CGRP (pg/ml) LOD=0.2 pg/ml LOD=0.02pg/ml Key validation properties of a CGRP assay Sensitivity at physiological levels Verified in tissues/collection media Dilutional linearity Specificity by immunodepletion Spike recovery Chai et al American Headache Society 2016

6 CGRP antagonist: migraine abortive Ocegepant (BIBN4096BS) IV Olesen et al, NEJM 2004 with permission

7 CGRP antagonist: migraine abortive Telcagepant (MK-0974) Ho et al, Lancet 2008, with permission Ho et al, Neurology 2008, with permission

8 CGRP antagonist: migraine prevention Ho et al, Cephalalgia 2016 with permission Ho et al, Neurology 2014 with permission

9 Biomarker of peripheral target engagement CGRP blockade inhibits capsaicin-induced dermal blood flow, Sets nominal CGRP-inhibitory activity required for peripheral activity Sinclair et al, BJCP 2010:69:15 with permission galcanezumab Capsaicin Vermeersch et al, JPET 2015 with permission Eli Lilly and Company, data on file

10 Dose-Exposure Relationship Monthly doses of galcanezumab 5, 50, 120 and 300 mg SC Galcanezumab Exposure LY Serum Concentration (nmol/l) Visit 5 Week 4 Doses: Visit 7 Week 8 5 mg Q4W 50 mg Q4W 120 mg Q4W 300 mg Q4W Visit 8 Week 10 Note: The middle line in each box plot represents the median; the top and bottom margins of the box represent the 75th and 25th percentiles; the whiskers extend to the 95th and 5th percentiles; data points outside the whiskers represent the points beyond the percentiles. Kielbasa et al Amer Acad Neurol 2016 Visit 9 Week 12 Weeks 4, 8, and 12 collected at 4 weeks postdose (trough level). Week 10 collected at midpoint of the dosing interval, at 2 weeks after the last dose (peak level)

11 CGRP antibodies: migraine prevention Galcanezumab reduces monthly migraine headache days LS Mean Overall Change from Baseline M igraine * * PBO (N=132) LY5mg (N=65) LY50mg (N=68) LY120mg (N=69) LY300mg (N=66) Migraine Headache Days * p-value = error bars represent 95% CI Skljarevski et al, Japanese Headache Society 2015

12 CGRP Bioassay Demonstrates Target Engagement CGRP concentrations rise after 5, 50, 120, and 300 mg SC CGRP Plasma Concentration (nmol/l) Visit 2 Baseline Placebo 5 mg Q4W 50 mg Q4W 120 mg Q4W 300 mg Q4W Visit 3 Baseline Visit 5 Week 4 Visit 7 Week 8 Visit 8 Week 10 Visit 9 Week 12 Note: The middle line in each box plot represents the median; the top and bottom margins of the box represent the 75th and 25th percentiles; the whiskers extend to the 95th and 5th percentiles; data points outside the whiskers represent the points beyond the percentiles. Using a drug-tolerant assay, baseline (predose) CGRP concentrations were assessed at Visit 2 and Visit 3. Weeks 4, 8, and 12 collected at 4 weeks postdose. Week 10 collected at mid-point of the dosing interval, at 2 weeks after the last dose. (Excludes measures below limit of assay quantification) Kielbasa et al, Amer Acad Neurol 2016

13 Drug Exposure-Biomarker Relationships Plasma CGRP levels plateau under an excess of galcanezumab CGRP Plasma Concentration (nmol/l) LY Serum Concentration (nmol/l) Placebo 5 mg Q4W 50 mg Q4W 120 mg Q4W 300 mg Q4W Kielbasa et al, Amer Acad Neurol 2016

14 Exposure-Efficacy Relationships Galcanezumab exposure vs reduction in migraine headache days Reduction in Headache Days Median Change from Baseline Number of Migraine Headache Days per 28-day Period Placebo All Doses Visit LY Serum Concentration (nmol/l) Quartiles Galcanezumab Exposure Kielbasa et al, Amer Acad Neurol 2016

15 Study CGAG vs. CGAH Mean Change in Monthly MHD Study CGAG Study CG AH 0 Placebo 0 Placebo Improvement LS Mean Change from Baseline (SE) GMB 120 mg GMB 240 mg p<.001 (at each month) -6 Baseline Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Improvement LS Mean Change from Baseline (SE) p<.001 GMB 120 mg GMB 240 mg (at each month) -6 Baseline Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Abbreviations: GMB=galcanezumab; LS=least square; MHD=migraine headache days; SE=standard error Note: not statistically significant between GMB doses at any month. Skljarevski et al, American Headache Society 2017 Stauffer et al, American Headache Society Eli Lilly and Company

16 Study CGAI Mean Change in Monthly MHD 0 Placebo Im provem ent LS M ean Change from Baseline (SE) GM B 120 m g GM B 240 m g **p <.0 1 p <.00 1 (at each m onth) ** -6 Baseline M onth 1 M onth 2 M onth 3 Note: not statistically significant between GMB doses at any month Detke et al, American Headache Society 2017

17 Questions and Next Steps Specific questions for CGRP biomarkers Tailoring and prediction of individual response Therapeutic hypothesis for other clinical conditions CGRP receptor availability in clinical conditions Key enablers of biomarker-based pain therapies Biomarker assay development/validation Biomarker association with clinical conditions Relationship between biomarker and disease state (ictal/interictal, acute/chronic, clinical subtypes) Biomarkers of target engagement

2017 Eli Lilly and Company

2017 Eli Lilly and Company Galcanezumab (LY2951742) CGRP Monoclonal Antibody for the Prevention of Migraine: Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies, ART01 and CGAB This information is provided in response

More information

1/25/2018 ARE CGRP ANTAGONISTS ANY BETTER THAN CURRENT EVIDENCE BASED TREATMENTS? Disclosures: Objectives: Headache Division

1/25/2018 ARE CGRP ANTAGONISTS ANY BETTER THAN CURRENT EVIDENCE BASED TREATMENTS? Disclosures: Objectives: Headache Division ARE CGRP ANTAGONISTS ANY BETTER THAN CURRENT EVIDENCE BASED TREATMENTS? Lawrence C Newman, MD, FAHS, FAAN Clinical Professor of Neurology Disclosures: Advisory Board: Alder, Allergan, Amgen, Lilly, Supernus,

More information

CGRP, MONOCLONAL ANTIBODIES AND SMALL MOLECULES (-GEPANTS)

CGRP, MONOCLONAL ANTIBODIES AND SMALL MOLECULES (-GEPANTS) CGRP, MONOCLONAL ANTIBODIES AND SMALL MOLECULES (-GEPANTS) Hans-Christoph Diener Senior Professor of Clinical Neurosciences University Duisburg-Essen Germany CGRP, Monoclonal Antibodies and Small Molecules

More information

Advances in the Treatment of Migraine

Advances in the Treatment of Migraine Advances in the Treatment of Migraine C. Philip O Carroll, M.D. Director Neurobehavioral Medicine Hoag Neurosciences Institute Guyuron B Headache, 2015;55:1464-1473 I m sorry your head hurts, sweetie.is

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Emgality) Reference Number: CP.PHAR.## Effective Date: 11.13.18 Last Review Date: 02.19 Line of Business: Commercial, TBD HIM*, Medicaid Revision Log See Important Reminder at the end

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association CGRP Page 1 of 13 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: CGRP (calcitonin gene-related peptide) Prime Therapeutics will review Prior Authorization requests

More information

A New Era of Migraine Management: The Challenging Landscape in Prevention

A New Era of Migraine Management: The Challenging Landscape in Prevention Provided by MediCom Worldwide, Inc. Supported by an educational grant from Teva Pharmaceuticals What is a Neuropeptide? Small chains of amino acids released by neural cells (neurons or glial cells) to

More information

CGRP, MABs and Small Molecules. David W. Dodick, M.D. Professor Department of Neurology Mayo Clinic Phoenix Arizona

CGRP, MABs and Small Molecules. David W. Dodick, M.D. Professor Department of Neurology Mayo Clinic Phoenix Arizona CGRP, MABs and Small Molecules David W. Dodick, M.D. Professor Department of Neurology Mayo Clinic Phoenix Arizona Disclosure Consulting: Allergan, Amgen, Alder, eneura, Colucid, Trigemina, Eli Lilly &

More information

HEADACHE PATHOPHYSIOLOGY

HEADACHE PATHOPHYSIOLOGY HEADACHE PATHOPHYSIOLOGY Andrew Charles, M.D. Professor Director, UCLA Goldberg Migraine Program Meyer and Renee Luskin Chair in Migraine and Headache Studies Director, Headache Research and Treatment

More information

Disclosures for Prof D L Hay. Research funding: Alder Biopharmaceuticals Inc. Consulting arrangements: Intarcia Therapeutics Inc.

Disclosures for Prof D L Hay. Research funding: Alder Biopharmaceuticals Inc. Consulting arrangements: Intarcia Therapeutics Inc. Disclosures for Prof D L Hay Research funding: Alder Biopharmaceuticals Inc. Consulting arrangements: Intarcia Therapeutics Inc. CGRP & Its Receptors Debbie L Hay University of Auckland, New Zealand There

More information

Migraine Migraine Age Specific Prevalence in the United States. Headache International Headache Society Classification

Migraine Migraine Age Specific Prevalence in the United States. Headache International Headache Society Classification 28 Primary Care Medicine Principles and Practice 29 October 28 Professor Peter J. Goadsby Peter.Goadsby@headache.ucsf.edu Department of Neurology Headache International Headache Society Classification

More information

Get ahead of the ACHE: Monoclonal Antibodies in Migraine Prevention

Get ahead of the ACHE: Monoclonal Antibodies in Migraine Prevention Get ahead of the ACHE: Monoclonal Antibodies in Migraine Prevention Amanda Janisch, PharmD PGY2 Ambulatory Care Pharmacy Resident MCHS SWMN, Mankato, MN 2018 MFMER slide-1 Disclosures No financial interest

More information

Disclosure. Learning Objectives 11/10/2017. The Best and Most Interesting Research from Last Year Cephalalgia

Disclosure. Learning Objectives 11/10/2017. The Best and Most Interesting Research from Last Year Cephalalgia The Best and Most Interesting Research from Last Year Cephalalgia David W. Dodick, M.D. Department of Neurology Mayo Clinic Scottsdale Arizona Disclosure Consulting services: Acorda, Allergan, Amgen, Alder,

More information

Migraine Controversies in Women s Health. Professor Peter J. Goadsby 5 December Department of Neurology

Migraine Controversies in Women s Health. Professor Peter J. Goadsby 5 December Department of Neurology Migraine 2008 Controversies in Women s Health 5 December 2008 Professor Peter J. Goadsby Peter.Goadsby@headache.ucsf.edu Department of Neurology Headache International Headache Society Classification Primary

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association CGRP Page 1 of 8 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: CGRP (calcitonin gene-related peptide) Prime Therapeutics will review Prior Authorization requests

More information

What is new in the migraine world! Modar Khalil Consultant neurologist Hull Royal Infirmary

What is new in the migraine world! Modar Khalil Consultant neurologist Hull Royal Infirmary What is new in the migraine world! Modar Khalil Consultant neurologist Hull Royal Infirmary Overview Understanding the burden Commonly used terms Acute therapy What we currently have What we are going

More information

PROMISE 2 Top-Line Data Results January 8, 2018

PROMISE 2 Top-Line Data Results January 8, 2018 PROMISE 2 Top-Line Data Results January 8, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking statements within the meaning of Section 27A

More information

OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA

OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition Joint Session with ACOFP, ACONP and AOAAM:

More information

ARxCH. Annual Review of Changes in Healthcare. Calcitonin Gene-Related Peptide Receptors and the Prevention of Migraines. Abstract

ARxCH. Annual Review of Changes in Healthcare. Calcitonin Gene-Related Peptide Receptors and the Prevention of Migraines. Abstract Calcitonin Gene-Related Peptide Receptors and the Prevention of Migraines Brian Schuler, PharmD Candidate 2018 1 1 University of Findlay College of Pharmacy Abstract Migraines are the third most prevalent

More information

Seeking the best care for acute migraine

Seeking the best care for acute migraine J Headache Pain (2002) 3:1 5 Springer-Verlag 2002 EDITORIAL Marcello Fanciullacci Seeking the best care for acute migraine M. Fanciullacci ( ) Headache Center, Department of Internal Medicine, University

More information

Zomig. Zomig / Zomig-ZMT (zolmitriptan) Description

Zomig. Zomig / Zomig-ZMT (zolmitriptan) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.22 Subject: Zomig Page: 1 of 5 Last Review Date: November 30, 2018 Zomig Description Zomig / Zomig-ZMT

More information

Migraine - whats on the horizon

Migraine - whats on the horizon Managing your migraine Edinburgh Saturday 10 th March 2018 Migraine - whats on the horizon Alok Tyagi Consultant Neurologist Glasgow Disclaimer I have received from Janssen Cillag, GSK, Allergan, Electrocore,

More information

Faculty Disclosures. Learning Objectives

Faculty Disclosures. Learning Objectives WWW.AMERICANHEADACHESOCIETY.ORG Pathophysiology Content developed by: Andrew C. Charles, MD, FAHS, Peter J. Goadsby, MD, PhD, FAHS Donna Gutterman, PharmD Faculty Disclosures ANDREW C. CHARLES, MD, FAHS

More information

EDITOR S PICK EMERGING TREATMENT OPTIONS IN MIGRAINE

EDITOR S PICK EMERGING TREATMENT OPTIONS IN MIGRAINE EDITOR S PICK As we approach an exciting time in migraine therapeutics, my Editor s Pick for this edition of EMJ Neurology is an article by Karsan et al., detailing the emerging treatment options to reduce

More information

Committed to Transforming the Treatment Paradigm for Migraine Prevention

Committed to Transforming the Treatment Paradigm for Migraine Prevention Committed to Transforming the Treatment Paradigm for Migraine Prevention 36th Annual J.P. Morgan Healthcare Conference January 8, 2018 Forward-Looking Statements This presentation and the accompanying

More information

DISCLOSURES UPDATE ON MIGRAINE EPIDEMIOLOGY, GENETICS, AND BASIC MECHANISMS. Grant Support Takeda

DISCLOSURES UPDATE ON MIGRAINE EPIDEMIOLOGY, GENETICS, AND BASIC MECHANISMS. Grant Support Takeda UPDATE ON MIGRAINE EPIDEMIOLOGY, GENETICS, AND BASIC MECHANISMS Andrew Charles, M.D. Professor of Neurology Director, UCLA Goldberg Migraine Program Meyer and Renee Luskin Chair in Migraine and Headache

More information

Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies: Adverse Effects. What Do We Really Know? A Literature Review

Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies: Adverse Effects. What Do We Really Know? A Literature Review Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies: Adverse Effects. What Do We Really Know? A Literature Review Authors: Theodoros Mavridis, 1,2 Chrysa Koniari, 1,2 Nikolaos Fakas, 2 *Dimos D.

More information

Page: 1 of 6. Aimovig (erenumab-aooe) injection, Ajovy (fremanezumab-vfrm) injection, Emgality (galcanezumab-gnim)

Page: 1 of 6. Aimovig (erenumab-aooe) injection, Ajovy (fremanezumab-vfrm) injection, Emgality (galcanezumab-gnim) Page: 1 of 6 Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Last Review Date: November 30, 2018 Description Aimovig (erenumab-aooe) injection, Ajovy (fremanezumab-vfrm)

More information

BMS for the Acute Treatment of Migraine: A Double-Blind, Randomized, Placebo Controlled, Dose-Ranging Trial

BMS for the Acute Treatment of Migraine: A Double-Blind, Randomized, Placebo Controlled, Dose-Ranging Trial BMS-927711 for the Acute Treatment of Migraine: A Double-Blind, Randomized, Placebo Controlled, Dose-Ranging Trial Ronald Marcus, MD Chief Medical Officer Spinifex Pharmaceuticals Migraine: Case Study

More information

British Journal of Clinical Pharmacology

British Journal of Clinical Pharmacology British Journal of Clinical Pharmacology DOI:10.1111/bcp.12547 Characterizing the PK/PD relationship for inhibition of capsaicin-induced dermal vasodilatation by MK-3207, an oral calcitonin gene related

More information

Sandler Family Trust. UCSF Medical Center. Headache A Review and Update. Headache The burden. Headache Group, UCSF Disclosure- by proportion*

Sandler Family Trust. UCSF Medical Center. Headache A Review and Update. Headache The burden. Headache Group, UCSF Disclosure- by proportion* 1 Headache A Review and Update Advances in Internal Medicine June 29 Professor Peter J. Goadsby Peter.Goadsby@headache.ucsf.edu Headache Group, UCSF Disclosure- by proportion Sandler Family Trust UCSF

More information

Differentiating Migraine from Other Headache Types to Target Treatment Peter J. Goadsby, MD, PhD

Differentiating Migraine from Other Headache Types to Target Treatment Peter J. Goadsby, MD, PhD Differentiating Migraine from Other Headache Types to Target Treatment Peter J. Goadsby, MD, PhD University of California, San Francisco San Francisco, CA King's College London London, England Learning

More information

Migraine and hormonal contraceptives

Migraine and hormonal contraceptives Migraine and hormonal contraceptives Department of Community Medicine, Systems Epidemiology University of Tromsø, November 2017 Nora Stensland Bugge Medical research student Presentation outline What is

More information

Calcitonin Gene-Related Peptide (CGRP) Inhibitors as Preventive Treatments for Patients with Episodic or Chronic Migraine: Effectiveness and Value

Calcitonin Gene-Related Peptide (CGRP) Inhibitors as Preventive Treatments for Patients with Episodic or Chronic Migraine: Effectiveness and Value Calcitonin Gene-Related Peptide (CGRP) Inhibitors as Preventive Treatments for Patients with Episodic or Chronic Migraine: Effectiveness and Value Background Draft Background and Scope December 4, 2017

More information

Regulatory Status FDA approved indication: Migranal Nasal Spray is indicated for the acute treatment of migraine headaches with or without aura (1).

Regulatory Status FDA approved indication: Migranal Nasal Spray is indicated for the acute treatment of migraine headaches with or without aura (1). Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.60 Subject: Migranal Nasal Spray Page: 1 of 5 Last Review Date: November 30, 2018 Migranal Nasal Spray

More information

A Controlled Trial of Erenumab for Episodic Migraine

A Controlled Trial of Erenumab for Episodic Migraine The new england journal of medicine Original Article A Controlled Trial of Erenumab for Episodic Migraine Peter J. Goadsby, M.D., Ph.D., Uwe Reuter, M.D., Yngve Hallström, M.D., Gregor Broessner, M.D.,

More information

A LOOK AT CGRP INHIBITORS FOR MIGRAINE PREVENTION JUNE 2018

A LOOK AT CGRP INHIBITORS FOR MIGRAINE PREVENTION JUNE 2018 JUNE 2018 Overview: About Migraine WHAT IS MIGRAINE? Migraine is a common, recurrent headache disorder that affects approximately 20% of women and 6-10% of men in the US. Migraine attacks are characterized

More information

UCNS Course A Review of ICHD-3b

UCNS Course A Review of ICHD-3b UCNS Course A Review of ICHD-3b Andrew D. Hershey, M.D., Ph.D., FAHS Endowed Chair and Director of Neurology Director, Cincinnati Children s Headache Center Professor of Neurology and Pediatrics University

More information

Understandable Statistics

Understandable Statistics Understandable Statistics correlated to the Advanced Placement Program Course Description for Statistics Prepared for Alabama CC2 6/2003 2003 Understandable Statistics 2003 correlated to the Advanced Placement

More information

Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date

Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date Review Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date Lanfranco Pellesi, Simona Guerzoni, and Luigi Alberto Pini Clinical Pharmacology in Drug Development 2017,

More information

Richard B. Lipton, 1 Joel Saper, 2 Messoud Ashina, 3 David Biondi, 4 Suman Bhattacharya, 4 Joe Hirman, 5 Barbara Schaeffler, 4 Roger Cady 4

Richard B. Lipton, 1 Joel Saper, 2 Messoud Ashina, 3 David Biondi, 4 Suman Bhattacharya, 4 Joe Hirman, 5 Barbara Schaeffler, 4 Roger Cady 4 A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of for the Preventive Treatment of Chronic Migraine: Results of the PROMISE-2 (PRevention Of Migraine via

More information

Disclosures. Triptans for Kids 5/16/13

Disclosures. Triptans for Kids 5/16/13 5/16/13 Disclosures Triptans for Kids Amy A. Gelfand, MD GelfandA@neuropeds.ucsf.edu Departments of Neurology and Pediatrics UCSF Child Neurology and Headache Center I receive grant funding from: NIH/NINDS

More information

Progestin-only methods Type or dose of progestagen

Progestin-only methods Type or dose of progestagen Progestin-only contraception and beneficial effects on migraine Conflicts of interest A d v ise r a n d le ctu re r fo r E X E LT IS Le ctu re s a n d A d v iso ry b o a rd s B aye r Le ctu re s a n d

More information

The Clinical Profile of Sumatriptan: Cluster Headache Key Words

The Clinical Profile of Sumatriptan: Cluster Headache Key Words Paper Eur Neurol 1994;34(suppl 2):35-39 P.J. Peter J. Goadsby Department of Neurology, The Prince Henry Hospital, Little Bay, Sydney, NSW, Australia The Clinical Profile of Sumatriptan: Cluster Headache

More information

Triptans: Nonresponse, Recurrence, and Serious AEs for Many Patients

Triptans: Nonresponse, Recurrence, and Serious AEs for Many Patients Efficacy, Safety, and Tolerability of Rimegepant 75 mg, an Oral CGRP Receptor Antagonist, for the Acute Treatment of Migraine: Results from a Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial,

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Ebbing M, Bønaa KH, Nygård O, et al. Cancer incidence and mortality after treatment with folic acid and vitamin B 1. JAMA. 9;3(19):119-1. etable 1. Circulating Levels of B

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Ajovy) Reference Number: CP.PHAR.## Effective Date: 10.30.18 Last Review Date: 02.19 Line of Business: Commercial, TBD HIM*, Medicaid Revision Log See Important Reminder at the end of

More information

The PACAP Receptor: A Novel Target for Migraine Treatment

The PACAP Receptor: A Novel Target for Migraine Treatment DEPARTMENT OF NEUROLOGY D A N I& S DANISH H H E AHEADACHE D A C H E CENTER C E N T E R Faculty of Health and Medical Sciences The PACAP Receptor: A Novel Target for Migraine Treatment Messoud Ashina, MD,

More information

ADVANCES IN MIGRAINE MANAGEMENT

ADVANCES IN MIGRAINE MANAGEMENT ADVANCES IN MIGRAINE MANAGEMENT Joanna Girard Katzman, M.D.MSPH Assistant Professor, Dept. of Neurology Project ECHO, Chronic Pain Program University of New Mexico Outline Migraine throughout the decades

More information

Tears of Pain SUNCT and SUNA A/PROFESSOR ARUN AGGARWAL RPAH PAIN MANAGEMENT CENTRE

Tears of Pain SUNCT and SUNA A/PROFESSOR ARUN AGGARWAL RPAH PAIN MANAGEMENT CENTRE Tears of Pain SUNCT and SUNA A/PROFESSOR ARUN AGGARWAL RPAH PAIN MANAGEMENT CENTRE IHS Classification 1989 (updated 2004) Primary Headaches 4 categories Migraine Tension-type Cluster and other trigeminal

More information

Committed to Transforming the Treatment Paradigm for Migraine Prevention

Committed to Transforming the Treatment Paradigm for Migraine Prevention June 14, 2018 Committed to Transforming the Treatment Paradigm for Migraine Prevention September 6, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking

More information

Zolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose response study

Zolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose response study is effective and well tolerated in Japanese patients with migraine: a dose response study F Sakai 1, M Iwata 2, K Tashiro 3, Y Itoyama 4, S Tsuji 5, Y Fukuuchi 6, G Sobue 7, K Nakashima 8 & M Morimatsu

More information

ACUTE TREATMENT FOR MIGRAINE. Cristina Tassorelli

ACUTE TREATMENT FOR MIGRAINE. Cristina Tassorelli The European Headache School 2012 ACUTE TREATMENT FOR MIGRAINE Cristina Tassorelli Headache Science Centre, IRCCS Neurological Institute C. Mondino Foundation - Pavia University Centre for Adaptive Disorders

More information

A New Class of Drugs for Migraine Prevention: Calcitonin Gene-Related Peptide (CGRP)- Directed Treatments

A New Class of Drugs for Migraine Prevention: Calcitonin Gene-Related Peptide (CGRP)- Directed Treatments A New Class of Drugs for Migraine Prevention: Calcitonin Gene-Related Peptide (CGRP)- Directed Treatments Samantha Otto-Meyer, PharmD Clinical Instructor PGY1 Community Pharmacy Resident Marlowe Djuric

More information

Lasmiditan (200 mg and 100 mg) Compared to Placebo for Acute Treatment of Migraine

Lasmiditan (200 mg and 100 mg) Compared to Placebo for Acute Treatment of Migraine (200 mg and 100 mg) Compared to for Acute Treatment of Migraine Bernice Kuca, M.S. 1 ; Linda A. Wietecha, B.S.N., M.S. 2 ; Paul H. Berg, M.S. 2 ; Sheena K. Aurora, M.D. 2 1 CoLucid Pharmaceuticals, Inc.,

More information

Sumatriptan Tablets, Nasal Spray (Imitrex), Nasal Powder (Onzetra Xsail), sumatriptan and naproxen sodium (Treximet tablets)

Sumatriptan Tablets, Nasal Spray (Imitrex), Nasal Powder (Onzetra Xsail), sumatriptan and naproxen sodium (Treximet tablets) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 0 Subject: Sumatriptan Page: 1 of 6 Last Review Date: November 30, 2018 Sumatriptan Description Sumatriptan

More information

Early onset of efficacy with erenumab in patients with episodic and chronic migraine

Early onset of efficacy with erenumab in patients with episodic and chronic migraine Schwedt et al. The Journal of Headache and Pain (2018) 19:92 https://doi.org/10.1186/s10194-018-0923-6 The Journal of Headache and Pain RESEARCH ARTICLE Early onset of efficacy with erenumab in patients

More information

The prevalence and characteristics of migraine among the Belgian working population

The prevalence and characteristics of migraine among the Belgian working population Acta neurol. belg., 2007, 107, 84-90 The prevalence and characteristics of migraine among the Belgian working population Guido MOENS 1,2, Kristien JOHANNIK 1, Chris VERBEEK 1,2 and Simon BULTERYS 1,2 1

More information

DISCLOSURES FUNCTIONS OF THE HYPOTHALAMUS

DISCLOSURES FUNCTIONS OF THE HYPOTHALAMUS NOVEL THERAPEUTIC TARGETS: THE HYPOTHALAMUS Andrew Charles, M.D. Professor Director, UCLA Goldberg Migraine Program Meyer and Renee Luskin Chair in Migraine and Headache Studies David Geffen School of

More information

Specific Objectives A. Topics to be lectured and discussed at the plenary sessions

Specific Objectives A. Topics to be lectured and discussed at the plenary sessions Specific Objectives A. Topics to be lectured and discussed at the plenary sessions 0. Introduction: Good morning ICHD-III! Let s start at the very beginning. When you read you begin with A-B-C, so when

More information

10/19/2018. Disclosures MIGRAINE PROPHYLAXIS. Objectives. Definitions Slide. What do you think the aooe stands for at the end of erenumab-aooe?

10/19/2018. Disclosures MIGRAINE PROPHYLAXIS. Objectives. Definitions Slide. What do you think the aooe stands for at the end of erenumab-aooe? Disclosures MIGRAINE PROPHYLAXIS Erenumab-aooe (AIMOVIG TM ) Calcitonin Gene Related Peptide Receptor Antagonist No conflicts of interest to disclose Chelsey Roscoe, PharmD PGY1 Resident - CTVHCS 2 3 Definitions

More information

Subject: Aimovig (erenumab) Original Effective Date: 7/10/2018. Policy Number: MCP-320. Revision Date(s):

Subject: Aimovig (erenumab) Original Effective Date: 7/10/2018. Policy Number: MCP-320. Revision Date(s): Subject: Aimovig (erenumab) Original Effective Date: 7/10/2018 Policy Number: MCP-320 Revision Date(s): Review Date(s): MCPC Approval Date: 7/10/2018 DISCLAIMER This Molina Clinical Policy (MCP) is intended

More information

DISCLOSURE OBJECTIVES

DISCLOSURE OBJECTIVES A New Class of Drugs for Migraine Prevention: Calcitonin Gene-Related Peptide (CGRP)- Directed Treatments Samantha Otto-Meyer, PharmD Clinical Instructor PGY1 Community Pharmacy Resident DISCLOSURE Dr.

More information

The Role of Allergies and Sinus Disorders in Headache & Facial Pain

The Role of Allergies and Sinus Disorders in Headache & Facial Pain The Role of Allergies and Sinus Disorders in Headache & Facial Pain Vincent T. Martin, MD Professor of Medicine Co-director of the Headache & Facial Pain Center University of Cincinnati College of Medicine

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Aimovig) Reference Number: CP.PHAR.128 Effective Date: 07.10.18 Last Review Date: 08.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy

More information

Calcitonin gene-related peptide in blood: is it increased in the external jugular vein during migraine and cluster headache?

Calcitonin gene-related peptide in blood: is it increased in the external jugular vein during migraine and cluster headache? J Headache Pain (2009) 10:137 143 DOI 10.1007/s10194-009-0112-8 REVIEW ARTICLE Calcitonin gene-related peptide in blood: is it increased in the external jugular vein during migraine and cluster headache?

More information

OTE. Aimovig : A Novel Therapy for Preventive Treatment of Migraine. Vol. 34, Issue 3 December Established 1985

OTE. Aimovig : A Novel Therapy for Preventive Treatment of Migraine. Vol. 34, Issue 3 December Established 1985 HAR Vol. 34, Issue 3 December 2018 M A N OTE Established 1985 Aimovig : A Novel Therapy for reventive Treatment of Migraine Michelle Vanderhoof, harmd Candidate I n the Global Burden of Disease Study 2015,

More information

Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects

Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects Pharm Res (2017) 34:1784 1795 DOI 10.1007/s11095-017-2183-6 RESEARCH PAPER Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine

More information

SPRING GROVE AREA SCHOOL DISTRICT. Course Description. Instructional Strategies, Learning Practices, Activities, and Experiences.

SPRING GROVE AREA SCHOOL DISTRICT. Course Description. Instructional Strategies, Learning Practices, Activities, and Experiences. SPRING GROVE AREA SCHOOL DISTRICT PLANNED COURSE OVERVIEW Course Title: Basic Introductory Statistics Grade Level(s): 11-12 Units of Credit: 1 Classification: Elective Length of Course: 30 cycles Periods

More information

Model-based quantification of the relationship between age and anti-migraine therapy

Model-based quantification of the relationship between age and anti-migraine therapy 6 Model-based quantification of the relationship between age and anti-migraine therapy HJ Maas, M Danhof, OE Della Pasqua Submitted to BMC. Clin. Pharmacol. Migraine is a neurological disease that affects

More information

Paradigm for Migraine Patients

Paradigm for Migraine Patients June Transforming 14, 2018 the Prevention Treatment Paradigm for Migraine Patients January 2019 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking

More information

Clinical case. Clinical case 3/15/2018 OVERVIEW. Refractory headaches and update on novel treatment. Refractory headache.

Clinical case. Clinical case 3/15/2018 OVERVIEW. Refractory headaches and update on novel treatment. Refractory headache. OVERVIEW Refractory headaches and update on novel treatment Definition of refractory headache Treatment approach Medications Neuromodulation In the pipeline Juliette Preston, MD OHSU Headache Center Refractory

More information

Incorporating Biologics Into Your Practice

Incorporating Biologics Into Your Practice Incorporating Biologics Into Your Practice Jeffrey M. Sobell MD Tufts University School of Medicine SkinCare Physicians Ora Clinical Research Disclosure Of Relationships With Industry Amgen AbbVie Celgene

More information

Clinical Learning Days November 10, 2017

Clinical Learning Days November 10, 2017 Migraine Clinical Learning Days November 10, 2017 Alyssa Lettich. MD Neurosciences Institute/Neurosciences Clinical Program Medical Director Headache Disclosures: none Learning Objectives: At the conclusion

More information

Calcitonin Gene-Related Peptide as a Biomarker in Migraine

Calcitonin Gene-Related Peptide as a Biomarker in Migraine Original Article J Neurol Res. 2017;7(6):103-107 Calcitonin Gene-Related Peptide as a Biomarker in Migraine Aktham Ismail Alemam a, b, Wafeek Mahmoud Alsheikh a, Ibrahim Alsayed Alahmar a Abstract Background:

More information

EXPEDITION3: A Phase 3 Trial of Solanezumab in Mild Dementia due to Alzheimer s Disease

EXPEDITION3: A Phase 3 Trial of Solanezumab in Mild Dementia due to Alzheimer s Disease EXPEDITION3: A Phase 3 Trial of in Mild Dementia due to Alzheimer s Disease Lawrence S. Honig, MD, PhD On behalf of the EXPEDITION3 Study Team Disclosure Statement I will discuss investigational use only.

More information

Calcitonin Gene Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine

Calcitonin Gene Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine The new england journal of medicine original article Calcitonin Gene Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine Jes Olesen, M.D., Hans-Christoph Diener, M.D.,

More information

Migraine Treatment What you need to know

Migraine Treatment What you need to know Migraine Treatment What you need to know DR NICOLE LIMBERG ST ANDREWS PLACE SPRING HILL www.migrainespecialist.com.au Migraine what is it? Primary neurobiological condition Waves of reduced brain activity

More information

Involvement of calcitonin gene-related peptide in migraine: regional cerebral blood flow and blood flow velocity in migraine patients

Involvement of calcitonin gene-related peptide in migraine: regional cerebral blood flow and blood flow velocity in migraine patients J Headache Pain (2008) 9:151 157 DOI 10.1007/s10194-008-0036-8 ORIGINAL Involvement of calcitonin gene-related peptide in migraine: regional cerebral blood flow and blood flow velocity in migraine patients

More information

Migraine Research Update Clinical and Scientific Highlights. David W. Dodick M.D. Professor Department of Neurology Mayo Clinic Phoenix Arizona

Migraine Research Update Clinical and Scientific Highlights. David W. Dodick M.D. Professor Department of Neurology Mayo Clinic Phoenix Arizona Migraine Research Update Clinical and Scientific Highlights David W. Dodick M.D. Professor Department of Neurology Mayo Clinic Phoenix Arizona 1 Objective Discuss some of the important advances in clinical

More information

Nothing to disclose 3

Nothing to disclose 3 Nothing to disclose 3 PREVALENCE AND BURDEN OF HEADACHE Patient with CDH IHS migraine Recurrent severe headache Severe headache Episodic headache Have had headache Entire population CDH=chronic daily headache.

More information

Supraorbital nerve stimulation Cefaly Device - FDA Approved for migraine prevention (also being investigated as acute therapy)

Supraorbital nerve stimulation Cefaly Device - FDA Approved for migraine prevention (also being investigated as acute therapy) NEUROSTIMULATION/NEUROMODULATION UPDATE Meyer and Renee Luskin Andrew Charles, M.D. Professor Luskin Chair in Migraine and Headache Studies Director, UCLA Goldberg Migraine Program David Geffen School

More information

Broad and clinically important benefits beyond the initial registrational endpoints are now reported.

Broad and clinically important benefits beyond the initial registrational endpoints are now reported. Biohaven Announces Robust Clinical Data with Single Dose Rimegepant That Defines Acute and Durable Benefits to Patients: The First Oral CGRP Receptor Antagonist to Deliver Positive Data on Pain Freedom

More information

MIGRAINE UPDATE. Objectives & Disclosures. Learn techniques used to diagnose headaches. Become familiar with medications used for headache treatment.

MIGRAINE UPDATE. Objectives & Disclosures. Learn techniques used to diagnose headaches. Become familiar with medications used for headache treatment. MIGRAINE UPDATE Karen L. Bremer, MD November 16, 2018 Objectives & Disclosures Learn techniques used to diagnose headaches. Become familiar with medications used for headache treatment. Disclosure: I am

More information

NOTES SUR LES TECHNOLOGIES DE LA SANTé EN émergence. Monoclonal antibodies to prevent migraine headaches

NOTES SUR LES TECHNOLOGIES DE LA SANTé EN émergence. Monoclonal antibodies to prevent migraine headaches NOTES SUR LES TECHNOLOGIES DE LA SANTé EN émergence Monoclonal antibodies to prevent migraine headaches 1 February 2018 (Document seulement disponible en anglais) Summary Migraine is a common, chronic,

More information

Opportunities in Pain Research with the NIH HEAL Initiative

Opportunities in Pain Research with the NIH HEAL Initiative Opportunities in Pain Research with the NIH HEAL Initiative Clinton Wright, M.D. Director, Division of Clinical Research National Institute of Neurological Disorders and Stroke, NIH September 20, 2018

More information

35 th Annual J.P. Morgan Healthcare Conference

35 th Annual J.P. Morgan Healthcare Conference 35 th Annual J.P. Morgan Healthcare Conference Forward Looking Statement This presentation includes forward-looking statements. All statements, other than statements of historical facts, regarding management's

More information

Emerging drugs for migraine treatment: an update

Emerging drugs for migraine treatment: an update Expert Opinion on Emerging Drugs ISSN: 1472-8214 (Print) 1744-7623 (Online) Journal homepage: http://www.tandfonline.com/loi/iemd20 Emerging drugs for migraine : an update Giorgio Lambru, Anna P. Andreou,

More information

Cholesterol; what are the future lipid targets?

Cholesterol; what are the future lipid targets? Cholesterol; what are the future lipid targets? lipidologist out-of-business in 5-10 years? G.Kees Hovingh dept of vascular medicine, Academic Medical Center g.k.hovingh@amc.uva.nl Disclosure - Consultant

More information

abstract n engl j med 377;22 nejm.org November 30,

abstract n engl j med 377;22 nejm.org November 30, The new england journal of medicine established in 1812 November 30, 2017 vol. 377 no. 22 for the Preventive Treatment of Chronic Migraine Stephen D. Silberstein, M.D., David W. Dodick, M.D., Marcelo E.

More information

6/20/2018. Chronic Migraine versus Chronic Pain: Similarities and Differences. Disclosure (36 months) Clinical Differences/Background

6/20/2018. Chronic Migraine versus Chronic Pain: Similarities and Differences. Disclosure (36 months) Clinical Differences/Background Chronic Migraine versus Chronic Pain: Similarities and Differences Clinical Differences/Background David W. Dodick, M.D. Professor Department of Neurology Mayo Clinic Phoenix Arizona Disclosure (36 months)

More information

Migraine Management. Dr Helen Brown Director of Neurology and Stroke The Princess Alexandra Hospital

Migraine Management. Dr Helen Brown Director of Neurology and Stroke The Princess Alexandra Hospital Migraine Management Dr Helen Brown Director of Neurology and Stroke The Princess Alexandra Hospital Referral Criteria for Migraine Migraine Management Migraine Diagnosis Spot on Health Migraine pathway

More information

Pharmacology & Therapeutics

Pharmacology & Therapeutics Pharmacology & Therapeutics 129 (2011) 332 351 Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Associate Editor: John Fozard Potential

More information

Atopic Dermatitis: Emerging therapies. Melinda Gooderham MSc MD FRCPC

Atopic Dermatitis: Emerging therapies. Melinda Gooderham MSc MD FRCPC Atopic Dermatitis: Emerging therapies Melinda Gooderham MSc MD FRCPC SKiN Centre for Dermatology, Peterborough Assistant Professor, Queen s University, Kingston ON Investigator, Probity Medical Research,

More information

Migraine Pathophysiology. Robert E. Shapiro, MD, PhD

Migraine Pathophysiology. Robert E. Shapiro, MD, PhD Migraine Pathophysiology Robert E. Shapiro, MD, PhD Disclosures Eli Lilly Member, Clinical Trials Data Monitoring Committee Learning Objectives By the end of this course participants will be able to describe:

More information

ACUTE MIGRAINE: OLD AND NEW DRUGS JOHN ROBROCK MD FORT WILLIAM FAMILY HEALTH TEAM

ACUTE MIGRAINE: OLD AND NEW DRUGS JOHN ROBROCK MD FORT WILLIAM FAMILY HEALTH TEAM ACUTE MIGRAINE: OLD AND NEW DRUGS JOHN ROBROCK MD FORT WILLIAM FAMILY HEALTH TEAM Conflict of Interest Declaration: Nothing to Disclose Presenter: John Robrock, MD Title of Presentation: Acute Migraine:

More information

8-May-2018 ICER OPEN COMMENT PERIOD ON CGRP INHIBITORS FOR MIGRAINE. Submitted electronically to:

8-May-2018 ICER OPEN COMMENT PERIOD ON CGRP INHIBITORS FOR MIGRAINE. Submitted electronically to: 8-May-2018 ICER OPEN COMMENT PERIOD ON CGRP INHIBITORS FOR MIGRAINE Submitted electronically to: publiccomments@icer-review.org Steven D. Pearson, MD, President Institute for Clinical and Economic Review

More information